152 related articles for article (PubMed ID: 32938212)
1. Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.
Bharmal M; Nolte S; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Pusceddu S; Hanna GJ; Hassel JC; Kiecker F; Ellers-Lenz B; Bajars M; Güzel G; Nghiem P; Hunger M; Schlichting M; Henry-Szatkowski M; D'Angelo SP
Future Oncol; 2020 Sep; 16(27):2089-2099. PubMed ID: 32938212
[No Abstract] [Full Text] [Related]
2. Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma.
Kaufman HL; Hunger M; Hennessy M; Schlichting M; Bharmal M
Future Oncol; 2018 Feb; 14(3):255-266. PubMed ID: 29219612
[TBL] [Abstract][Full Text] [Related]
3. Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
Lambert J; Marrel A; D'Angelo SP; Burgess MA; Chmielowski B; Fazio N; Gambichler T; Grob JJ; Lebbé C; Robert C; Russell J; Güzel G; Bharmal M
Patient; 2020 Aug; 13(4):457-467. PubMed ID: 32472503
[TBL] [Abstract][Full Text] [Related]
4. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
5. Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma.
Bharmal M; Nolte S; Henry-Szatkowski M; Hennessy M; Schlichting M
Health Qual Life Outcomes; 2020 May; 18(1):145. PubMed ID: 32430019
[TBL] [Abstract][Full Text] [Related]
6. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
8. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
[TBL] [Abstract][Full Text] [Related]
9. A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.
Chang WC; Lin AY; Hsu JC; Wu CE; Goh C; Chou P; Kuo K; Chang A; Palencia R
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1399. PubMed ID: 33934577
[TBL] [Abstract][Full Text] [Related]
10. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; Georges S; Ellers-Lenz B; Shah P; Güzel G; Nghiem P
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301810
[TBL] [Abstract][Full Text] [Related]
11. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial.
Bharmal M; Guillemin I; Marrel A; Arnould B; Lambert J; Hennessy M; Fofana F
Orphanet J Rare Dis; 2018 Jun; 13(1):95. PubMed ID: 29914528
[TBL] [Abstract][Full Text] [Related]
12. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
D'Angelo SP; Hunger M; Brohl AS; Nghiem P; Bhatia S; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Schlichting M; Hennessy MH; Bharmal M
Cancer Immunol Immunother; 2019 Apr; 68(4):609-618. PubMed ID: 30721341
[TBL] [Abstract][Full Text] [Related]
13. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Xiong H; Guezel G; Nghiem PT
ESMO Open; 2021 Dec; 6(6):100290. PubMed ID: 34715570
[TBL] [Abstract][Full Text] [Related]
14. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort.
Levy S; Aarts MJB; Eskens FALM; Keymeulen KBMI; Been LB; Grünhagen D; van Akkooi A; Jalving M; Tesselaar MET
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32948651
[TBL] [Abstract][Full Text] [Related]
15. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
16. Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Lanitis T; Proskorovsky I; Ambavane A; Hunger M; Zheng Y; Bharmal M; Phatak H
Adv Ther; 2019 Sep; 36(9):2327-2341. PubMed ID: 31350728
[TBL] [Abstract][Full Text] [Related]
17. Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations.
Munhoz RR; Cayol F; Corrales L; Gerson R; Tilli M; Barreto EO; Sánchez Castillo JO; Schmerling RA; Cinat G
Cancer Immunol Immunother; 2021 Apr; 70(4):1031-1036. PubMed ID: 33104838
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy.
Chandra S; Zheng Y; Pandya S; Yu T; Kearney M; Wang L; Kim R; Phatak H
Future Oncol; 2020 Nov; 16(31):2521-2536. PubMed ID: 32883109
[No Abstract] [Full Text] [Related]
19. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
Ascierto PA; Orlova K; Grignani G; Dudzisz-Śledź M; Fenig E; Chiarion Sileni V; Fazio N; Samimi M; Mortier L; Gebhardt C; Kramkimel N; Steven N; Bechter O; Arance A; Benincasa E; Kostkova L; Costa N; Lorigan P
Int J Cancer; 2021 Dec; 149(11):1926-1934. PubMed ID: 34310716
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights.
Bharmal M; Marrel A; Hennessy M; Fofana F; Lambert J; Arnould B
J Comp Eff Res; 2018 Sep; 7(9):881-890. PubMed ID: 30107762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
